Elicio Therapeutics Will Present Cancer Study Data
The company is scheduled to share new findings from its Phase 2 trial at the ESMO Congress in Madrid this October.
Updated on Sept. 24, 2026 in Cancer

Live Poll
Should pharmaceutical companies focus resources on developing standardized off-the-shelf cancer immunotherapies?
Elicio Therapeutics will present late-breaking data from its Phase 2 AMPLIFY-7P study during the ESMO Congress on October 23, 2026. The presentation will offer new pre-specified analyses regarding the use of ELI-002 7P in patients with resected pancreatic ductal adenocarcinoma.
Why it matters
These findings aim to clarify the clinical benefit of the immunotherapy candidate following the study missing its primary disease-free survival endpoint. The data will help shape the company's development strategy for a potential Phase 3 clinical trial.
The study enrolled 144 patients across 24 U.S. clinical sites to evaluate ELI-002 7P versus observation. KRAS mutations are known to drive approximately 25% of all solid tumors.
The players
Elicio Therapeutics
This biotechnology company focuses on developing lymph node-targeted immunotherapies to treat various types of cancer.
ESMO Congress
Organized by the European Society for Medical Oncology, this annual event brings together experts to discuss the latest advancements in oncology research.
The details
The upcoming oral presentation, titled LBA83, evaluates the effectiveness of lymph node-targeted amphiphile immunotherapy in patients with mKRAS-driven pancreatic cancer. Elicio Therapeutics plans to discuss these results with the global oncology community to better understand the therapy's potential performance.
Timeline
October 23, 2026: Presentation of AMPLIFY-7P study results at the ESMO Congress.
October 23-27, 2026: Duration of the ESMO Congress 2026 in Madrid, Spain.
The Big Picture
This presentation follows the pattern of clinical data dissemination established at the ESMO Congress 2026. The findings represent a key contribution to the ongoing evaluation of immunotherapies within the broader oncology landscape.
The presentation provides critical insights for oncologists and patients regarding the potential efficacy of new immunotherapy treatments for pancreatic cancer. These results will ultimately influence the design and availability of future Phase 3 clinical trials.
The takeaway
The upcoming results highlight the iterative nature of oncology research where Phase 2 outcomes serve as a foundation for refining complex immunotherapy strategies. Researchers and medical professionals will use these analyses to determine if the current therapeutic approach warrants large-scale testing.
What happens next
A webcast of the session will be available on the ESMO Virtual Platform within 12 hours following the presentation on October 23, 2026.
Further reading
For more information on the latest developments in oncology treatments, visit the Cancer section.
More information
For additional details on the company's research, visit the Elicio Therapeutics company website.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should pharmaceutical companies focus resources on developing standardized off-the-shelf cancer immunotherapies?



